Fullerton Management Pte Ltd - Net Worth and Insider Trading

Fullerton Management Pte Ltd Net Worth

The estimated net worth of Fullerton Management Pte Ltd is at least $424 Million dollars as of 2025-06-03. Fullerton Management Pte Ltd is the of Ocumension Therapeutics and owns about 54,169,400 shares of Ocumension Therapeutics (HKSE:01477) stock worth over $424 Million. Details can be seen in Fullerton Management Pte Ltd's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Fullerton Management Pte Ltd has not made any transactions after 2020-07-10 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Fullerton Management Pte Ltd

Fullerton Management Pte Ltd Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Fullerton Management Pte Ltd owns 1 companies in total, including Ocumension Therapeutics (HKSE:01477) .

Click here to see the complete history of Fullerton Management Pte Ltd’s form 4 insider trades.

Insider Ownership Summary of Fullerton Management Pte Ltd

Ticker	Company	Transaction Date	Type of Owner
HKSE:01477	Ocumension Therapeutics	2020-07-10

Fullerton Management Pte Ltd Latest Holdings Summary

Fullerton Management Pte Ltd currently owns a total of 1 stock. Fullerton Management Pte Ltd owns 54,169,400 shares of Ocumension Therapeutics (HKSE:01477) as of July 10, 2020, with a value of $424 Million.

Latest Holdings of Fullerton Management Pte Ltd

Ticker	Company	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
HKSE:01477	Ocumension Therapeutics	2020-07-10	54,169,400	7.82	423,604,708

Holding Weightings of Fullerton Management Pte Ltd

Fullerton Management Pte Ltd Form 4 Trading Tracker

According to the SEC Form 4 filings, Fullerton Management Pte Ltd has made a total of 1 transactions in Ocumension Therapeutics (HKSE:01477) over the past 5 years, including 0 buys and 0 sells. The most-recent trade in Ocumension Therapeutics is the sale of 0 shares on July 10, 2020, which brought Fullerton Management Pte Ltd around $0.

Insider Trading History of Fullerton Management Pte Ltd

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Fullerton Management Pte Ltd Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Fullerton Management Pte Ltd Ownership Network

Ownership Network List of Fullerton Management Pte Ltd

No Data

Ownership Network Relation of Fullerton Management Pte Ltd

Fullerton Management Pte Ltd Owned Company Details

What does Ocumension Therapeutics do?

Who are the key executives at Ocumension Therapeutics?

Fullerton Management Pte Ltd is the of Ocumension Therapeutics. Other key executives at Ocumension Therapeutics include 2101 Beneficial owner Liu Ye , 2101 Beneficial owner 6 Dimensions Capital, L.P. , and 2201 Interest of corporation controlled by you ZHANG Qiping .

Ocumension Therapeutics (HKSE:01477) Insider Trades Summary

Over the past 18 months, Fullerton Management Pte Ltd made no insider transaction in Ocumension Therapeutics (HKSE:01477). Other recent insider transactions involving Ocumension Therapeutics (HKSE:01477) include a net sale of 0 shares made by Liu Ye , a net sale of 1,500,000 shares made by Temasek Holdings (private) Limited , and a net sale of 0 shares made by Alcon Pharmaceuticals Ltd .

In summary, during the past 3 months, insiders sold 0 shares of Ocumension Therapeutics (HKSE:01477) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 1,500,000 shares of Ocumension Therapeutics (HKSE:01477) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,500,000 shares.

Ocumension Therapeutics (HKSE:01477)'s detailed insider trading history can be found in Insider Trading Tracker table.

Ocumension Therapeutics Insider Transactions

No Available Data

Fullerton Management Pte Ltd Mailing Address

Above is the net worth, insider trading, and ownership report for Fullerton Management Pte Ltd. Currently GuruFocus does not have mailing address information for Fullerton Management Pte Ltd.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.